December 25, 2025 07:26 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tarique Rahman returns to Bangladesh after 17 years | Shocking killing inside AMU campus: teacher shot dead during evening walk | Horror on Karnataka highway: sleeper bus bursts into flames after truck crash, 9 killed | PM Modi attends Christmas service at Delhi church, sends message of love and compassion | Delhi erupts over lynching of Hindu man in Bangladesh; protest outside High Commission | Targeted killing sparks global outrage: American lawmakers condemn mob lynching of Hindu man in Bangladesh | Assam on a ‘powder keg’: Himanta Biswa Sarma flags demographic shift, Chicken’s Neck fears | Bangladesh on edge: Student leader shot as pre-poll violence deepens after Hadi killing | Historic deal sealed: India, New Zealand sign landmark Free Trade Agreement in record time | Supreme court snubs urgent plea to stop PMO’s chadar offering at Ajmer Sharif
Covaxin | AIIMS
Image Credit: Wikimedia Commons/tweeted by @IndianEmbassyTR

AIIMS Delhi to start screening 6-12 yrs children for Covaxin trial from Tuesday

| @indiablooms | Jun 15, 2021, at 05:57 am

New Delhi/IBNS: The All India Institute of Medical Sciences (AIIMS), New Delhi will begin the selection process of children in the age group of 6-12 years for the clinical trials of Bharat Biotech's Covaxin on Tuesday, said Dr Sanjay Rai, professor at the Centre for Community Medicine at AIIMS Delhi, said a media report.

After the recruitment of children in the age group is done, the process for clinical trials for children between 2 to 6 years of age will be started, the report added.

The screening for clinical trials in the age group of 12 to 18 is already completed and they have been administered with a single dose of the vaccine, it said.

AIIMS, Patna has already started the paediatric trials of Covaxin on children between 12 to 18 years from June 3.

On May 12, the Drugs Controller General of India (DCGI) had granted permission to conduct the second and third phase of clinical trials of Covaxin on children in the age group of  2 to 18 years.

The decision for mass inoculation drive for children was taken after experts warned that the disease could take a serious shape among them if there is a change in virus behaviour or epidemiology dynamics.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.